

The diverse roles of protein kinase C in pancreatic β -cell function

Trevor J. Biden¹, Carsten Schmitz-Peiffer, James G. Burchfield, Ebru Gurisik, James Cantley, Christopher J. Mitchell and Lee Carpenter

Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010, Australia

Abstract

Members of the serine/threonine PKC (protein kinase C) family perform diverse functions in multiple cell types. All members of the family are activated in signalling cascades triggered by occupation of cell surface receptors, but the cPKC (conventional PKC) and nPKC (novel PKC) isoforms are also responsive to fatty acid metabolites. PKC isoforms are involved in various aspects of pancreatic β -cell function, including cell proliferation, differentiation and death, as well as regulation of secretion in response to glucose and muscarinic receptor agonists. Recently, the nPKC isoform, PKC ϵ , has also been implicated in the loss of insulin secretory responsiveness that underpins the development of Type 2 diabetes.

Introduction

The PKC (protein kinase C) family of serine/threonine protein kinases comprises a total of ten isoforms, and is subdivided into three groups based on sequence homology and mechanisms of activation [1]. The cPKC (conventional PKC) (PKC α , β and γ) and nPKC (novel PKC) subgroups (PKC δ , ϵ , η and θ) are both activated by DAG (diacylglycerol), but the cPKCs are additionally sensitive to Ca²⁺. Both these subgroups are activated downstream of receptors that couple with phospholipase C, phosphoinositide hydrolysis and DAG generation. The aPKC (atypical PKC) isoforms (PKC ζ and PKC ι/λ) constitute a third group within the PKC family, and are independent of both Ca²⁺ and DAG. Instead, these kinases can be activated in response to receptors that stimulate phosphoinositide 3-kinase.

or protocols to down-regulate PKC, have clearly established at least a partial requirement for PKC activation in the potentiation of insulin secretion due to muscarinic receptor agonists [10–12]. cPKCs are the most strongly implicated isoforms [13]. However, there is also good evidence that PKC activation acts as a feedback inhibitor in the G_q signalling pathway [11,14–17]. It would not be surprising if this effect were mediated by activation of different PKC isoforms to those responsible for the predominant stimulation of secretion, although this has not been investigated extensively. An additional consideration is that muscarinic cholinergic receptors couple with the hydrolysis of both PtdIns and PtdIns(4,5)P₂ [18,19], so it is possible that different PKC isoforms might be activated downstream of these two signalling events, but this has not been demonstrated directly.

Receptor-mediated PKC activation in β -cells

Multiple PKC isoforms are expressed in pancreatic islets and β -cell lines, including PKC α , β _{II}, δ , ϵ , ζ and ι [2–6]. Moreover, pharmacological activation of the cPKCs and nPKCs is sufficient to promote insulin secretion provided a stimulus to raise intracellular Ca²⁺ is also included [7]. The relevance of these findings was quickly established in the context of a role for PKC in mediating secretion in response to agonists acting on receptors coupled with the canonical G_q/phospholipase C signalling pathway [8]. Best studied of these are agonists such as acetylcholine or carbamoylcholine that activate muscarinic cholinergic receptors and thereby stimulate multiple isoforms of PKC [3,4,9]. Inhibitor studies,

PKC and GSIS (glucose-stimulated insulin secretion)

Because glucose promotes phosphoinositide hydrolysis in β -cells, secondary to voltage-gated Ca²⁺ influx and a Ca²⁺-dependent stimulation of phospholipase C [20], it was envisioned that the DAG/PKC pathway might also be relevant to GSIS. This was strengthened by suggestions that DAG could also be generated via *de novo* synthesis from glucose [21,22]. More recent evidence favours a mechanism whereby alterations in endogenous lipid metabolism lead to increases in PKC activators such as DAG or CoA derivatives of long-chain FAs (fatty acids) [LCACs (long-chain acyl-carnitines)] [23–25]. According to this model, glucose leads to increases in malonyl-CoA, which subsequently inhibits β -oxidation via actions on the key regulatory enzyme, CPT1 (carnitine palmitoyltransferase 1). This shifts endogenous FA metabolism towards esterification pathways at the expense of β -oxidation [23]. A similar mechanism is implicated in the potentiation of GSIS by non-esterified FAs [26].

Key words: glucose-stimulated insulin secretion, insulin secretion, lipotoxicity, pancreatic β -cell, protein kinase C (PKC), Type 2 diabetes.

Abbreviations used: DAG, diacylglycerol; FA, fatty acid; GLP-1, glucagon-like peptide 1; GSIS, glucose-stimulated insulin secretion; IGF-1, insulin-like growth factor-1; PKC, protein kinase C; aPKC, atypical PKC; cPKC, conventional PKC; nPKC, novel PKC.

¹To whom correspondence should be addressed (email t.biden@garvan.org.au).

However, because whole islets are not readily amenable to overexpression strategies, and because of the lack of truly isoform-specific inhibitors, the role of PKC activation in GSIS has remained controversial. Nevertheless, glucose does appear to activate classical PKC isoforms (particularly PKC α) in a Ca²⁺-dependent manner, at least as demonstrated by their translocation to the plasma membrane [27–29]. Glucose also alters the subcellular localization of PKC ϵ [28,30], although the ultimate destination varies between studies [31,32]. Translocation is not necessarily the same thing as functional activation, however, and demonstrations of glucose-stimulated phosphorylation of PKC substrates in β -cells have been inconsistent [6,11,33–35]. This might be explained by activation of protein phosphatases by glucose [8], which would tend to counter the functional consequences of PKC stimulation. Thus phosphorylation of classical PKC substrates in islets was shown to be modest and transient, unless phosphatase inhibitors were also employed during glucose stimulation [6].

Investigations of whether PKC activation is required for GSIS were initially based on the use of relatively non-specific inhibitors or down-regulation of PKC activity by chronic exposure to phorbol esters. These produced variable results [11,33,36,37], which might be partially explained by species differences between rats and mice. The use of more specific inhibitors, capable of selectively targeting cPKCs, resulted in only modest alterations in GSIS, but clearly inhibited secretion in response to phorbol esters under the same conditions [6,13,38]. Consistent with these findings, the use of recombinant adenoviruses to overexpress wild-type or kinase-dead (dominant-negative) PKC α constructs did not alter either first- or second-phase GSIS in perfused rat islets [6]. A similar approach in another laboratory resulted in a slight diminution of second-phase GSIS with PKC α kinase-dead virus, but this was based on batch incubation of islets [39]. Collectively these studies suggest that activation of cPKCs plays, at most, a minor role in GSIS.

Knockout mouse models have been used more recently to address roles of nPKCs and aPKCs in β -cell function. Deletion of aPKC ι/λ resulted in decreased GSIS [40], but this was related to a role in general β -cell differentiation rather than stimulus–secretion coupling itself (see below). A partial requirement for PKC δ in GSIS has also been postulated from knockout mouse studies [41], although activation of this isoform by glucose could not be demonstrated in this or several earlier reports [29,32]. Moreover, a role in GSIS was not supported when kinase-dead PKC δ was overexpressed in isolated rat islets using adenovirus [6]. Therefore a role in secretion for this isoform appears less well established than its generally pro-apoptotic function in pancreatic β -cells [42–44].

Glucose tolerance or insulin excursions during whole body glucose tolerance tests were not impaired in PKC ϵ -knockout mice, nor was GSIS altered when measured *ex vivo* [45]. Similarly, a cell-permeant, peptide inhibitor of PKC ϵ did not inhibit the secretory response to glucose using isolated islets [45]. In contrast, a cell-impermeant form of this peptide did inhibit GSIS, possibly as a result of manipulations for permeabilizing the islets to facilitate peptide entry [28]. In

other studies, overexpression of a variety of PKC ϵ constructs in β -cells pointed to roles for this PKC isoform in regulating secretion in response to glibenclamide [31], or inositol hexakisphosphate [46], but GSIS was not specifically examined. Moreover, secretion was not assayed directly in these studies, but extrapolated from changes in membrane capacitance.

PKC and the regulation of β -cell mass

In addition to the above described role for PKC ι/λ in controlling β -cell differentiation [40], the aPKCs are strongly implicated as regulators of β -cell proliferation. PKC ζ is essential for full proliferative responses due to growth factors such as GLP-1 (glucagon-like peptide 1) [47], IGF-1 (insulin-like growth factor-1) [48], PTHrP (parathyroid hormone-related protein) and HGF (hepatocyte growth factor) [49]. Moreover, PKC ζ can positively regulate expression of the key β -cell transcription factor PDX-1 (pancreatic duodenal homeobox-1) in response to either IGF-1 [48] or glucose [50]. There is also some evidence for involvement of nPKC isoforms in regulating β -cell mass, and activation of these isoforms by FAs could account for the disruptions in growth factor receptor signalling that are caused when β -cells are chronically exposed to lipid *in vitro* [25]. In whole animals the situation is more complex, since islet cell mass and proliferation are augmented by high-fat diets, as part of the compensatory response to the accompanying insulin resistance. These increases in β -cell mass and proliferation were not observed in the PKC ϵ -knockout mice, although there was no difference in islet mass between when wild-type and PKC ϵ ^{-/-} animals were maintained on a chow diet [45]. This might indicate a requirement for PKC ϵ in the β -cell proliferation that accompanies insulin resistance. But the situation is complicated by an accompanying improvement in whole-body glucose tolerance [45], and so might simply represent an adaptive response whereby proliferation is normalized under conditions where β -cell compensation is no longer required.

PKC in β -cell dysfunction

Type 2 diabetes represents the inability of pancreatic β -cells to compensate, via enhanced insulin secretion, for the insulin resistance that accompanies obesity. This failure to compensate is characterized by both secretory defects, especially in GSIS, and a relative loss of β -cell mass due to enhanced apoptosis. Both these features can be repeated *in vitro* by chronically exposing β -cells to FAs. This raises the possibility of PKC involvement in mediating β -cell dysfunction in response to FAs, in a manner akin to that of the postulated role of PKCs in causing insulin resistance.

The first direct evidence of a potential involvement of PKC in β -cell dysfunction was the observation that overexpression of kinase-dead PKC δ partially protected against lipoapoptosis [44]. More recently, an unexpected role in the development of insulin-secretory defects in models of lipotoxicity was demonstrated using PKC ϵ -knockout mice [45]. As discussed above, deletion of PKC ϵ resulted in a

normalization of glucose tolerance in fat-fed mice, which was due to an enhancement of insulin availability rather than improved insulin-sensitivity. This was confirmed by comparing GSIS from islets isolated from wild-type and PKC ϵ -knockout animals chronically exposed to elevated FAs in tissue culture. The secretory defects induced under these conditions were prevented by deletion of PKC ϵ , and likewise GSIS was improved in islets of diabetic *db/db* mice when treated *ex vivo* with a PKC ϵ inhibitory peptide. In all cases, *in vivo* and *ex vivo*, the enhancement of insulin secretion was dependent on a diabetic milieu or prior lipid exposure; unimpaired GSIS was not altered by functional inhibition of PKC ϵ [45]. Although multiple mechanisms might contribute to this phenotype, the most likely appears to involve an enhancement of the amplification pathway of GSIS. Thus deletion of PKC ϵ restored the partitioning of FA metabolism away from β -oxidation towards esterification products [45]. In wild-type, but not PKC ϵ ^{-/-} islets, this partitioning is inhibited by chronic lipid exposure.

Inhibition of PKC as a therapy for improving β -cell dysfunction

The recently documented involvement of PKC ϵ in β -cell dysfunction might be of potential relevance to the future treatment of Type 2 diabetes. An inhibitor of PKC ϵ would appear to possess advantages over existing therapies for promoting insulin secretion. First, inhibiting PKC ϵ appears to act very proximally to the site of impaired secretion, which is very different from the mode of action of therapeutics such as sulfonylureas or GLP-1 agonists. These override the secretory defect rather than directly addressing the cause of the impaired secretion. Mechanistically, sulfonylureas or GLP-1 agonists augment intracellular Ca²⁺, and so could complement administration of a PKC ϵ inhibitor, which is predicted to act by amplifying events downstream of Ca²⁺ signals. Another advantage is that PKC ϵ deletion selectively augmented the first phase of GSIS [45], which is crucial for regulating glucose tolerance, and which is lost early in the development of Type 2 diabetes. Finally, the effects of inhibiting PKC ϵ in β -cells were complemented by a reduction in hepatic insulin clearance. Both aspects contributed to the enhanced availability of insulin [45]. Taken together, these features suggest that a single therapy, based on inhibition of PKC ϵ , could act at multiple sites, in manners different from, and therefore complimentary to, existing treatments for Type 2 diabetes. However, much more work is needed to determine whether PKC inhibitors will ever fulfil their clinical potential. On the other hand, further study of the role of PKC ϵ in regulating glucose homeostasis could yield valuable insights into the mechanisms underlying β -cell dysfunction, and further our knowledge of the amplification pathway of GSIS itself.

Work in our laboratory has been supported by grants from the National Health and Medical Research Council, Diabetes Australia

Research Trust, Eli Lilly Australia and the Juvenile Diabetes Research Foundation.

References

- Mellor, H. and Parker, P.J. (1998) The extended protein kinase C superfamily. *Biochem. J.* **332**, 281–292
- Knutson, K.L. and Hoenig, M. (1994) Identification and subcellular characterization of protein kinase-C isoforms in insulinoma β -cells and whole islets. *Endocrinology* **135**, 881–886
- Tian, Y.M., Urquidi, V. and Ashcroft, S.J. (1996) Protein kinase C in β -cells: expression of multiple isoforms and involvement in cholinergic stimulation of insulin secretion. *Mol. Cell. Endocrinol.* **119**, 185–193
- Tang, S.H. and Sharp, G.W. (1998) Atypical protein kinase C isozyme ζ mediates carbachol-stimulated insulin secretion in RINm5F cells. *Diabetes* **47**, 905–912
- Kaneto, H., Suzuma, K., Sharma, A., Bonner-Weir, S., King, G.L. and Weir, G.C. (2002) Involvement of protein kinase C β 2 in *c-myc* induction by high glucose in pancreatic β -cells. *J. Biol. Chem.* **277**, 3680–3685
- Carpenter, L., Mitchell, C.J., Xu, Z.Z., Poronnik, P., Both, G.W. and Biden, T.J. (2004) PKC α is activated but not required during glucose-induced insulin secretion from rat pancreatic islets. *Diabetes* **53**, 53–60
- Zawalich, W., Brown, C. and Rasmussen, H. (1983) Insulin secretion: combined effects of phorbol ester and A23187. *Biochem. Biophys. Res. Commun.* **117**, 448–455
- Jones, P.M. and Persaud, S.J. (1998) Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic β -cells. *Endocr. Rev.* **19**, 429–461
- Mogami, H., Zhang, H., Suzuki, Y., Urano, T., Saito, N., Kojima, I. and Petersen, O.H. (2003) Decoding of short-lived Ca²⁺ influx signals into long term substrate phosphorylation through activation of two distinct classes of protein kinase C. *J. Biol. Chem.* **278**, 9896–9904
- Persaud, S.J., Jones, P.M., Sugden, D. and Howell, S.L. (1989) The role of protein kinase C in cholinergic stimulation of insulin secretion from rat islets of Langerhans. *Biochem. J.* **264**, 753–758
- Arkhammar, P., Nilsson, T., Welsh, M., Welsh, N. and Berggren, P.O. (1989) Effects of protein kinase C activation on the regulation of the stimulus-secretion coupling in pancreatic β -cells. *Biochem. J.* **264**, 207–215
- Thams, P., Capito, K., Hedeskov, C.J. and Kofod, H. (1990) Phorbol-ester-induced down-regulation of protein kinase C in mouse pancreatic islets: potentiation of phase 1 and inhibition of phase 2 of glucose-induced insulin secretion. *Biochem. J.* **265**, 777–787
- Harris, T.E., Persaud, S.J. and Jones, P.M. (1996) Atypical isoforms of PKC and insulin secretion from pancreatic β -cells: evidence using G δ 6976 and Ro 31-8220 as PKC inhibitors. *Biochem. Biophys. Res. Commun.* **227**, 672–676
- Biden, T.J., Vallar, L. and Wollheim, C.B. (1988) Regulation of inositol 1,4,5-trisphosphate metabolism in insulin-secreting RINm5F cells. *Biochem. J.* **251**, 435–440
- Yamatani, T., Chiba, T., Kadowaki, S., Hishikawa, R., Yamaguchi, A., Inui, T., Fujita, T. and Kawazu, S. (1988) Dual action of protein kinase C activation in the regulation of insulin release by muscarinic agonist from rat insulinoma cell line (RINr). *Endocrinology* **122**, 2826–2832
- Li, G.D., Regazzi, R., Ullrich, S., Pralong, W.F. and Wollheim, C.B. (1990) Potentiation of stimulus-induced insulin secretion in protein kinase C-deficient RINm5F cells. *Biochem. J.* **272**, 637–645
- Verspohl, E.J. and Wienecke, A. (1998) The role of protein kinase C in the desensitization of rat pancreatic islets to cholinergic stimulation. *J. Endocrinol.* **159**, 287–295
- Biden, T.J., Prugue, M.L. and Davison, A.G. (1992) Evidence for phosphatidylinositol hydrolysis in pancreatic islets stimulated with carbamylcholine: kinetic analysis of inositol polyphosphate metabolism. *Biochem. J.* **285**, 541–549
- Mitchell, C.J., Kelly, M.M., Blewitt, M., Wilson, J.R. and Biden, T.J. (2001) Phospholipase C- γ mediates the hydrolysis of phosphatidylinositol, but not of phosphatidylinositol 4,5-bisphosphate, in carbamylcholine-stimulated islets of Langerhans. *J. Biol. Chem.* **276**, 19072–19077
- Biden, T.J., Peter-Riesch, B., Schlegel, W. and Wollheim, C.B. (1987) Ca²⁺-mediated generation of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in pancreatic islets: studies with K⁺, glucose, and carbamylcholine. *J. Biol. Chem.* **262**, 3567–3571
- Peter-Riesch, B., Fathi, M., Schlegel, W. and Wollheim, C.B. (1988) Glucose and carbachol generate 1,2-diaclyglycerols by different mechanisms in pancreatic islets. *J. Clin. Invest.* **81**, 1154–1161

- 22 Wolf, B.A., Easom, R.A., McDaniel, M.L. and Turk, J. (1990) Diacylglycerol synthesis *de novo* from glucose by pancreatic islets isolated from rats and humans. *J. Clin. Invest.* **85**, 482–490
- 23 Nolan, C.J., Madiraju, M.S., Delghingaro-Augusto, V., Peyot, M.L. and Prentki, M. (2006) Fatty acid signaling in the β -cell and insulin secretion. *Diabetes* **55** (Suppl. 2), S16–S23
- 24 Yaney, G.C. and Corkey, B.E. (2003) Fatty acid metabolism and insulin secretion in pancreatic β cells. *Diabetologia* **46**, 1297–1312
- 25 Wrede, C.E., Dickson, L.M., Lingohr, M.K., Briaud, I. and Rhodes, C.J. (2003) Fatty acid and phorbol ester-mediated interference of mitogenic signaling via novel protein kinase C isoforms in pancreatic β -cells (INS-1). *J. Mol. Endocrinol.* **30**, 271–286
- 26 Alcazar, O., Qiu-yue, Z., Gine, E. and Tamarit-Rodriguez, J. (1997) Stimulation of islet protein kinase C translocation by palmitate requires metabolism of the fatty acid. *Diabetes* **46**, 1153–1158
- 27 Ganesan, S., Calle, R., Zawalich, K., Greenawalt, K., Zawalich, W., Shulman, G.I. and Rasmussen, H. (1992) Immunocytochemical localization of α -protein kinase-C in rat pancreatic β -cells during glucose-induced insulin secretion. *J. Cell Biol.* **119**, 313–324
- 28 Yedovitzky, M., Mochlyrosen, D., Johnson, J.A., Gray, M.O., Ron, D., Abramovitch, E., Cerasi, E. and Neshler, R. (1997) Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic β -cells. *J. Biol. Chem.* **272**, 1417–1420
- 29 Pinton, P., Tsuboi, T., Ainscow, E.K., Pozzan, T., Rizzuto, R. and Rutter, G.A. (2002) Dynamics of glucose-induced membrane recruitment of protein kinase C β II in living pancreatic islet β -cells. *J. Biol. Chem.* **277**, 37702–37710
- 30 Zaitsev, S.V., Efendic, S., Arkhammar, P., Bertorello, A.M. and Berggren, P.O. (1995) Dissociation between changes in cytoplasmic free Ca²⁺ concentration and insulin secretion as evidenced from measurements in mouse single pancreatic islets. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 9712–9716
- 31 Mendez, C.F., Leibiger, I.B., Leibiger, B., Hoy, M., Gromada, J., Berggren, P.O. and Bertorello, A.M. (2003) Rapid association of protein kinase C ϵ with insulin granules is essential for insulin exocytosis. *J. Biol. Chem.* **278**, 44753–44757
- 32 Warwar, N., Efendic, S., Ostenson, C.G., Haber, E.P., Cerasi, E. and Neshler, R. (2006) Dynamics of glucose-induced localization of PKC isoenzymes in pancreatic β -cells: diabetes-related changes in the GK rat. *Diabetes* **55**, 590–599
- 33 Easom, R.A., Hughes, J.H., Landt, M., Wolf, B.A., Turk, J. and McDaniel, M.L. (1989) Comparison of effects of phorbol esters and glucose on protein kinase C activation and insulin secretion in pancreatic islets. *Biochem. J.* **264**, 27–33
- 34 Owada, S., Larsson, O., Arkhammar, P., Katz, A.I., Chibalin, A.V., Berggren, P.O. and Bertorello, A.M. (1999) Glucose decreases Na⁺,K⁺-ATPase activity in pancreatic β -cells: an effect mediated via Ca²⁺-independent phospholipase A₂ and protein kinase C-dependent phosphorylation of the α -subunit. *J. Biol. Chem.* **274**, 2000–2008
- 35 Gonelle-Gispert, C., Costa, M., Takahashi, M., Sadoul, K. and Halban, P. (2002) Phosphorylation of SNAP-25 on serine-187 is induced by secretagogues in insulin-secreting cells, but is not correlated with insulin secretion. *Biochem. J.* **368**, 223–232
- 36 Hii, C.S., Jones, P.M., Persaud, S.J. and Howell, S.L. (1987) A re-assessment of the role of protein kinase C in glucose-stimulated insulin secretion. *Biochem. J.* **246**, 489–493
- 37 Zawalich, W.S., Zawalich, K.C. and Kelley, G.G. (1995) Regulation of insulin release by phospholipase C activation in mouse islets: differential effects of glucose and neurohumoral stimulation. *Endocrinology* **136**, 4903–4909
- 38 Zawalich, W.S. and Zawalich, K.C. (2001) Effects of protein kinase C inhibitors on insulin secretory responses from rodent pancreatic islets. *Mol. Cell. Endocrinol.* **177**, 95–105
- 39 Zhang, H., Nagasawa, M., Yamada, S., Mogami, H., Suzuki, Y. and Kojima, I. (2004) Bimodal role of conventional protein kinase C in insulin secretion from rat pancreatic β -cells. *J. Physiol.* **561**, 133–147
- 40 Hashimoto, N., Kido, Y., Uchida, T., Matsuda, T., Suzuki, K., Inoue, H., Matsumoto, M., Ogawa, W., Maeda, S., Fujihara, H. et al. (2005) PKC α regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic β -cells. *J. Clin. Invest.* **115**, 138–145
- 41 Uchida, T., Iwashita, N., Ohara-Imaizumi, M., Ogihara, T., Nagai, S., Choi, J.B., Tamura, Y., Tada, N., Kawamori, R., Nakayama, K.I. et al. (2007) Protein kinase C δ plays a non-redundant role in insulin secretion in pancreatic β cells. *J. Biol. Chem.* **282**, 2707–2716
- 42 Carpenter, L., Cordery, D. and Biden, T.J. (2001) Protein kinase C δ activation by interleukin-1 β stabilizes inducible nitric oxide synthase mRNA in pancreatic β -cells. *J. Biol. Chem.* **276**, 5368–5374
- 43 Carpenter, L., Cordery, D. and Biden, T.J. (2002) Inhibition of protein kinase C δ protects rat INS-1 cells against interleukin-1 β and streptozotocin-induced apoptosis. *Diabetes* **51**, 317–324
- 44 Eitel, K., Staiger, H., Rieger, J., Mischak, H., Brandhorst, H., Brendel, M.D., Bretzel, R.G., Haring, H.U. and Kellerer, M. (2003) Protein kinase C δ activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. *Diabetes* **52**, 991–997
- 45 Schmitz-Peiffer, C., Laybutt, D.R., Burchfield, J.G., Gurisik, E., Narasimhan, S., Mitchell, C.J., Pedersen, D.J., Braun, U., Cooney, G.J., Leitges, M. and Biden, T.J. (2007) Inhibition of PKC ϵ improves glucose-stimulated insulin secretion and reduces insulin clearance. *Cell Metab.* **6**, 320–328
- 46 Hoy, M., Berggren, P.O. and Gromada, J. (2003) Involvement of protein kinase C ϵ in inositol hexakisphosphate-induced exocytosis in mouse pancreatic β -cells. *J. Biol. Chem.* **278**, 35168–35171
- 47 Buteau, J., Foisy, S., Rhodes, C.J., Carpenter, L., Biden, T.J. and Prentki, M. (2001) Protein kinase C ζ activation mediates glucagon-like peptide-1-induced pancreatic β -cell proliferation. *Diabetes* **50**, 2237–2243
- 48 Hennig, A.M., Fritsche, A., Strack, V., Weigert, C., Mischak, H., Borboni, P., Renn, W., Haring, H.U. and Kellerer, M. (2002) PKC ζ enhances insulin-like growth factor 1-dependent mitogenic activity in the rat clonal β cell line RIN 1046-38. *Biochem. Biophys. Res. Commun.* **290**, 85–90
- 49 Vasavada, R.C., Wang, L., Fujinaka, Y., Takane, K.K., Rosa, T.C., Mellado-Gil, J.M., Friedman, P.A. and Garcia-Ocana, A. (2007) Protein kinase C ζ activation markedly enhances β -cell proliferation: an essential role in growth factor-mediated β -cell mitogenesis. *Diabetes* **56**, 2732–2743
- 50 Furukawa, N., Shirota, T., Araki, E., Kaneko, K., Todaka, M., Matsumoto, K., Tsuruzoe, K., Motoshima, H., Yoshizato, K., Kishikawa, H. and Shichiri, M. (1999) Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and G α 6976-insensitive pathway. *Endocr. J.* **46**, 43–58

Received 21 April 2008
doi:10.1042/BST0360916